Historic Partnership between the Weizmann Institute of Science and Institut Curie
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.
Collaborative research programs
This partnership will extend to many disciplines, including physics,
chemistry, cellular biology, epigenetics, genetics, immunology and
single cell approaches, imagery and data collection. The complementarity
of the research between the various groups at Institut Curie and at the
Weizmann Institute has been recognized in particular at the occasion of
joint scientific workshops held regularly alternatively in Paris and
Rehovot. Each research program will be organized around a pair of
researchers with a scientist from Institut Curie and a scientist from
the Weizmann Institute of Sciences, who will receive support on the
annual basis. This partnership also includes exchanges of scientists and
a Curie-Weizmann symposium organized every two years, with alternate
locations in Rehovot, Israel, and in Paris, which will be focused on one
of the subjects of research cooperation.
To finance the start of
this cooperation, Institut Curie and the Weizmann Institute of Sciences
will finance this research program for €200,000 each, and will organize
a joint fundraiser with philanthropists and corporate sponsors.
Projects with high hopes
There are numerous common interests
between the two Institutes. They can range from the description of
defects in cell nuclei to the mechanics of cell migration, or the
behavior of neural networks. A few examples of exciting ongoing projects
are highlighted below.
During his sabbatical visit at Institut
Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in
several projects ranging from cell migration to collective cell
behaviors and neuron growth. For instance, he developed a theory in
collaboration with Raphael Voituriez (Sorbonne University), which
explains the observations of the team of Matthieu Piel (Institut Curie)
on the links between persistence and speed of migrating cells. This
theory gave rise to collaborative developments between these three teams
to predict important aspects of the migratory behavior of immune cells.
He
also collaborated with Pascal Silberzan at Institut Curie to understand
the behavior of cells packed at very high density on a surface. This
joint work combining experiments and theory, has highlighted the
importance of an intrinsic biological ageing of the cell population.
This project has helped understanding how cells can come to an arrest
while maintaining a capacity to respond to external perturbations such
as an injury.
Elisha Moses (Weizmann Institute) has a longstanding
interaction with the group of Professor Jean-Louis Viovy (Institut
Curie), now headed by Stéphanie Descroix, on the applications of
microfluidic devices to the study of living neuronal networks. He spent
three months in Paris, during which he and Dr. Catherine Villard of the
Descroix lab developed an optogenetic assay for guiding axonal growth.
This work has the potential for controlling growth of neurons and of
neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two
talented researchers who were working on the project as students, have
now graduated and branched off into very interesting conceptual and
practical applications of this approach.
An important complementarity
The two institutions are both
highly complementary and display many mutually common attributes.
Institut
Curie is the premier research center in France conducting cancer
research, including all facets of carcinogenesis. Its research center
brings together 1,200 researchers working in 12 joint research units
organized in four areas based on natural scientific interactions and
robust medical potentiality. A strong advocate of international
cooperation , it welcomes more than 80 nationalities. Equipped with
advanced technology platforms, it is an important resource for
researchers around the world. Institut Curie is also a state-of-the-art
hospital complex that provides care and support for all cancer types and
welcomes more than 50,000 patients each year. It has developed
particularly innovative treatments directly from the work of its
research center. Institut Curie also trains students in science and
cancer research with the goal of increasing the knowledge about the
topic.
The Weizmann Institute of Science is among the ten premier
institutes of fundamental research in the world: 2,500 scientists work
on its campus in Rehovot in the complementary fields of mathematics and
computer science, physics, biology, chemistry, and biochemistry. The
Weizmann Institute of Science has a long history of research and
discoveries rooted in a mission of advancement of science for the
benefit of humanity; cancer research accounts for 40% of the total
budget of the Institute, which shapes and hosts a large part of the
leadership in Israel and contributes to the advancement and
understanding of scientific issues among all audiences.
Both
institutions have powerful means of technology transfer that leverage
the discoveries of their labs for the benefit of patients, whether
through the creation of medications, medical devices or other
technologies.
A shared vision of science
Science at the service of people
- this is the best way to describe the credo of the two institutes, both
of which were founded upon great personalities who have made an
important mark in the history of the world.
Chaim Weizmann, chemist
and author of many discoveries and publications, is the founder of the
Weizmann Institute, and was the first president of the State of Israel
between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the
Radium Institute in 1909. The first female professor and holder of a
chair position at the Sorbonne, the first woman to win two Nobel prizes
and be enshrined at the Pantheon in Paris on her own merit. In many
ways, these two scientists have had a remarkable journey.
But
beyond these prestigious founders, the two institutes share the same
vision of science, at the service of people and driven by strong values,
the same curiosity for discovery and knowledge at the service of human
health.
The
Weizmann Institute of Science and Institut Curie also share a common
belief that international collaborations in the field of institut-curie.org
science and the exchange of ideas across interdisciplinary boundaries
can accelerate progress to the benefit of humanity.
It is this
common ground which today enables this collaboration to take root and
which will tomorrow allow us to multiply efforts and as a result enjoy
major new discoveries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005638/en/
Contact information
Yohan Philippe
yohan.philippe@curie.fr
+33
(0)1 56 24 55 53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
